Literature DB >> 22560972

The effects of 5-fluoruracil treatment on 3'-fluoro-3'-deoxythymidine (FLT) transport and metabolism in proliferating and non-proliferating cultures of human tumor cells.

David A Plotnik1, Lena J McLaughlin, Kenneth A Krohn, Jeffrey L Schwartz.   

Abstract

UNLABELLED: 3'-Fluoro-3'-deoxythymidine (FLT) positron emission tomography (PET) has been proposed for imaging thymidylate synthase (TS) inhibition. Agents that target TS and shut down de novo synthesis of thymidine monophosphate increase the uptake and retention of FLT in vitro and in vivo because of a compensating increase in the salvage pathway. Increases in both thymidine kinase-1 (TK1) and the equilibrative nucleoside transporter hENT1 have been reported to underlie this effect. We examined whether the effects of one TS inhibitor, 5-fluorouracil (5FU), on FLT uptake require proliferating cells and whether the effects are limited to increasing TK1 activity.
METHODS: The effects of 5FU on FLT transport and metabolism, TK1 activity, and cell cycle progression were evaluated in the human tumor cell line, A549, maintained as either a proliferating or non-proliferating culture.
RESULTS: There were dose-dependent increases in FLT uptake that peaked after a 10 μM 5FU exposure and then declined to baseline levels or below at higher doses in both proliferating and non-proliferating cultures. The dose-dependence for FLT uptake was mirrored by changes in TK1 activity. S phase fraction did not correlate with FLT uptake in proliferating cultures. Chemical inhibition of hENT1 reduced overall levels of FLT uptake but did not affect the low dose increase in FLT uptake.
CONCLUSIONS: 5FU only affects FLT uptake in proliferating A549 cells and increases in FLT uptake are directly related to increased TK1 activity. Our studies did not support a role for hENT1 in the increased uptake of FLT after exposure to 5FU. Our studies with A549 cells support the suggestion that FLT-PET could provide a measure of TS inhibition in vivo.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22560972      PMCID: PMC3435469          DOI: 10.1016/j.nucmedbio.2012.03.009

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  35 in total

1.  Chk1-dependent slowing of S-phase progression protects DT40 B-lymphoma cells against killing by the nucleoside analogue 5-fluorouracil.

Authors:  H M R Robinson; R Jones; M Walker; G Zachos; R Brown; J Cassidy; D A F Gillespie
Journal:  Oncogene       Date:  2006-04-17       Impact factor: 9.867

2.  Control of dTTP pool size by anaphase promoting complex/cyclosome is essential for the maintenance of genetic stability.

Authors:  Po-Yuan Ke; Yuan-Yeh Kuo; Chuan-Mei Hu; Zee-Fen Chang
Journal:  Genes Dev       Date:  2005-08-15       Impact factor: 11.361

Review 3.  New PET tracers for evaluation of solid tumor response to therapy.

Authors:  S M Larson; H Schoder
Journal:  Q J Nucl Med Mol Imaging       Date:  2009-04       Impact factor: 2.346

4.  The role of human nucleoside transporters in uptake of 3'-deoxy-3'-fluorothymidine.

Authors:  Robert J Paproski; Amy M L Ng; Sylvia Y M Yao; Kathryn Graham; James D Young; Carol E Cass
Journal:  Mol Pharmacol       Date:  2008-07-31       Impact factor: 4.436

Review 5.  Positron emission tomography measurement of tumor metabolism and growth: its expanding role in oncology.

Authors:  Anthony F Shields
Journal:  Mol Imaging Biol       Date:  2006 May-Jun       Impact factor: 3.488

6.  Altered tissue 3'-deoxy-3'-[18F]fluorothymidine pharmacokinetics in human breast cancer following capecitabine treatment detected by positron emission tomography.

Authors:  Laura M Kenny; Kaiyumars B Contractor; Justin Stebbing; Adil Al-Nahhas; Carlo Palmieri; Sami Shousha; R Charles Coombes; Eric O Aboagye
Journal:  Clin Cancer Res       Date:  2009-10-27       Impact factor: 12.531

7.  Imaging pharmacodynamics of the alpha-folate receptor-targeted thymidylate synthase inhibitor BGC 945.

Authors:  Radhakrishna G Pillai; Martin Forster; Meg Perumal; Fraser Mitchell; Julius Leyton; Franklin I Aibgirhio; Oksana Golovko; Ann L Jackman; Eric O Aboagye
Journal:  Cancer Res       Date:  2008-05-15       Impact factor: 12.701

8.  Redistribution of nucleoside transporters to the cell membrane provides a novel approach for imaging thymidylate synthase inhibition by positron emission tomography.

Authors:  Meg Perumal; Radhakrishna G Pillai; Henryk Barthel; Julius Leyton; John R Latigo; Martin Forster; Fraser Mitchell; Ann L Jackman; Eric O Aboagye
Journal:  Cancer Res       Date:  2006-09-01       Impact factor: 12.701

9.  Elevation of radiolabelled thymidine uptake in RIF-1 fibrosarcoma and HT29 colon adenocarcinoma cells after treatment with thymidylate synthase inhibitors.

Authors:  Kawai Yau; Patricia Price; Radhakrishma G Pillai; Eric Aboagye
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-03-28       Impact factor: 9.236

10.  [18F]FDG and [18F]FLT uptake in human breast cancer cells in relation to the effects of chemotherapy: an in vitro study.

Authors:  W G E Direcks; S C Berndsen; N Proost; G J Peters; J Balzarini; M D Spreeuwenberg; A A Lammertsma; C F M Molthoff
Journal:  Br J Cancer       Date:  2008-08-05       Impact factor: 7.640

View more
  8 in total

1.  Evaluation of arginine deiminase treatment in melanoma xenografts using (18)F-FLT PET.

Authors:  Lars Stelter; Simon Fuchs; Achim A Jungbluth; Gerd Ritter; Valerie A Longo; Pat Zanzonico; Nathanael Raschzok; Igor M Sauer; John S Bomalaski; Steven M Larson
Journal:  Mol Imaging Biol       Date:  2013-12       Impact factor: 3.488

2.  [18F]FDG and [18F]FLT positron emission tomography imaging following treatment with belinostat in human ovary cancer xenografts in mice.

Authors:  Mette Munk Jensen; Kamille Dumong Erichsen; Camilla Bardram Johnbeck; Fredrik Björkling; Jacob Madsen; Peter Buhl Jensen; Maxwell Sehested; Liselotte Højgaard; Andreas Kjær
Journal:  BMC Cancer       Date:  2013-04-01       Impact factor: 4.430

3.  Response Monitoring with [18F]FLT PET and Diffusion-Weighted MRI After Cytotoxic 5-FU Treatment in an Experimental Rat Model for Colorectal Liver Metastases.

Authors:  Sandra Heskamp; Linda Heijmen; Danny Gerrits; Janneke D M Molkenboer-Kuenen; Edwin G W Ter Voert; Kathrin Heinzmann; Davina J Honess; Donna-Michelle Smith; John R Griffiths; Sabrina Doblas; Ralph Sinkus; Peter Laverman; Wim J G Oyen; Arend Heerschap; Otto C Boerman
Journal:  Mol Imaging Biol       Date:  2017-08       Impact factor: 3.488

4.  Increased intratumoral fluorothymidine uptake levels following multikinase inhibitor sorafenib treatment in a human renal cell carcinoma xenograft model.

Authors:  Masahiro Murakami; Songji Zhao; Yan Zhao; Wenwen Yu; Chowdhury Nusrat Fatema; Ken-Ichi Nishijima; Masahiro Yamasaki; Mitsuyoshi Takiguchi; Nagara Tamaki; Yuji Kuge
Journal:  Oncol Lett       Date:  2013-07-12       Impact factor: 2.967

5.  Dynamic PET evaluation of elevated FLT level after sorafenib treatment in mice bearing human renal cell carcinoma xenograft.

Authors:  Naoyuki Ukon; Songji Zhao; Wenwen Yu; Yoichi Shimizu; Ken-Ichi Nishijima; Naoki Kubo; Yoshimasa Kitagawa; Nagara Tamaki; Kei Higashikawa; Hironobu Yasui; Yuji Kuge
Journal:  EJNMMI Res       Date:  2016-12-12       Impact factor: 3.138

6.  Early detection of thymidylate synthase resistance in non-small cell lung cancer with FLT-PET imaging.

Authors:  Xiao Chen; Yizeng Yang; Sharyn Katz
Journal:  Oncotarget       Date:  2017-07-31

7.  Early detection of pemetrexed-induced inhibition of thymidylate synthase in non-small cell lung cancer with FLT-PET imaging.

Authors:  Xiao Chen; Yizeng Yang; Ian Berger; Urooj Khalid; Akash Patel; Jenny Cai; Michael D Farwell; Corey Langer; Charu Aggarwal; Steven M Albelda; Sharyn I Katz
Journal:  Oncotarget       Date:  2017-04-11

8.  Dexamethasone pretreatment impairs the thymidylate synthase inhibition mediated flare in thymidine salvage pathway activity in non-small cell lung cancer.

Authors:  Xiao Chen; Yizeng Yang; Sharyn I Katz
Journal:  PLoS One       Date:  2018-08-24       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.